12 results about "Pheochromocytoma" patented technology

The invention provides a monoclonal antibody of NMN and application and a product thereof, and relates to the technical field of biology. According to the NMN monoclonal antibody provided by the invention, the research of the inventor finds that the monoclonal antibody can specifically recognize NMN, the properties of high titer, good gradient, specificity, repeatability, stability and the like of the monoclonal antibody meet the requirements of an NMN detection kit, and the monoclonal antibody can be used for diagnosing pheochromocytoma.

The present invention provides the application of the construction of biomarkers and risk models based on amino acid metabolism-related genes in predicting the diagnosis, treatment and prognosis of pheochromocytoma, belonging to the technical field of tumor diagnostic markers. We found through research that the amino acid metabolism-related genes DDC and / or SYT11 show high expression levels in pheochromocytoma, have an obvious impact on the diagnosis and prognosis of pheochromocytoma, can accurately evaluate the prognostic risk of patients, and can become a new target for the treatment of pheochromocytoma. At the same time, we constructed a risk model that can assist in judging the diagnosis and treatment of patients with the expression levels of DDC, SYT11, GCLM, PSMB7, TYRO3 and / or AGMAT as parameters. This risk model has strong predictive ability for the selection of immunotherapy methods, can be used as an important indicator for the selection of immunotherapy methods, can identify patients with high-risk factors at an early stage, and provides an important basis for the precise formulation of treatment strategies and individualized treatment decisions.

The invention discloses a method for rapidly and simultaneously detecting catecholamine substances and creatinine in urine, relates to the technical field of clinical content and concentration analysis and detection of nerve substances, and adopts LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry) to perform system integration development of multiple indexes. Seven items, including dopamine, epinephrine, noradrenaline, alphinephrine, noradrenaline, homovanillic acid and vanillic mandelic acid, of urine catecholamine and metabolites are developed and used for detecting pheochromocytoma and paraganglioma; the seven items include the dopamine, the epinephrine, the noradrenaline, the alphinephrine, the homovanillic acid and the vanillic mandelic acid; seven indexes can be detected at a time, the kit can be used for detecting random urine, great convenience is brought to patients, meanwhile, the seven indexes are analyzed together, and specificity and sensitivity of PPGL detection are improved; random urine detection needs the ratio of seven indexes to creatinine, creatinine in urine is often used as an internal reference and is used for concentration correction when substances in urine are excreted, the concentration of catecholamine and catecholamine metabolites in urine is corrected according to the content of creatinine in urine, and the influence of renal functions and drinking water factors on results is reduced.

The invention provides an image segmentation method and device for pheochromocytoma, and a medium. The method comprises the steps: carrying out the convolution of a pheochromocytoma image, and obtaining detail features; multi-scale features are obtained according to image embedding by using convolution layers of different scales, new image embedding is obtained by splicing the obtained multi-scale features and original image embedding, query is obtained according to the new image embedding, keys and values are obtained according to detail features, attention calculation is performed, and multiple global features are obtained; encoding the point prompt as prompt embedding; decoding according to the prompt embedding and the fourth global feature to obtain a first coding feature; decoding according to the first global feature, the second global feature, the third global feature and the first coding feature to obtain a second coding feature; performing image segmentation according to the first coding feature and the second coding feature to obtain an image segmentation result; the capability of capturing detail features is enhanced, and the accuracy and integrity of medical image segmentation are improved.

Embodiments of the present application provide a pheochromocytoma medical image segmentation method and device, equipment and medium. Among them, the method comprises: acquiring a pheochromocytoma medical image; inputting the pheochromocytoma medical image into a pheochromocytoma segmentation model for image segmentation to obtain a segmentation result of the pheochromocytoma medical image, the pheochromocytoma segmentation model is composed of a semi-supervised segmentation model and a SAM-Med3D segmentation model, the semi-supervised segmentation model includes a shared encoder and multiple independent decoders, a multi-scale attention module is arranged on the encoding path of the encoder, the multi-scale attention module is used to strengthen the extraction of key features of pheochromocytoma, and the pseudo label is selected by competition and comparison among the outputs of the multiple decoders, and the position information generated by the multiple decoders is used as the source of mask prompt information of the SAM-Med3D segmentation model. Based on this, the embodiments of the present application can improve the automatic segmentation performance of the pheochromocytoma medical image.

The invention relates to the technical field of metal organic framework materials, and discloses a chiral metal organic framework material as well as a preparation method and application thereof. The chiral metal organic framework material provided by the invention has a definite chiral microenvironment, a high specific surface area and good physical and chemical stability, can realize high-selectivity recognition of specific chiral substances according to a stereo matching mechanism, and is simple in synthesis process and easy to prepare; a chiral cyclic chemiluminescence sensor constructed based on the material integrates the advantages of high selectivity, high sensitivity, simplicity and convenience in operation and the like, can be directly used for rapid identification and accurate quantification of chiral substances in complex biological samples such as urine, serum and the like, and does not need complex derivatization or purification steps; an efficient and reliable new tool is provided for on-site rapid analysis and preliminary screening of diseases such as hypertension and pheochromocytoma.

The invention discloses a construction method and application of an Alzheimer's disease cell model. Specifically, a beta-amyloid protein oligomer (A beta oligomer) is used for stimulating highly differentiated rat adrenal pheochromocytoma cells (PC-12 cells) so as to simulate physiological changes of neurons in brains of patients with the Alzheimer's disease and construct the cell model of the Alzheimer's disease. The Alzheimer's disease cell model constructed by the method can simulate the physiological status of neurons in the brain of a patient with Alzheimer's disease in vitro more truly and reliably, and an important experimental material is provided for studying the pathogenesis of Alzheimer's disease and screening drugs for preventing or treating Alzheimer's disease.

This invention proposes a method and culture medium for culturing human pheochromocytoma organoids, belonging to the field of organoid culture technology. The method includes the following steps: S1. Pheochromocytoma treatment; S2. ON-TOP seeding of pheochromocytoma and induction culture; S3. Embedding of pheochromocytoma in a gel and maintenance culture. This method is simple, rapid, and efficient. Due to the characteristics of pheochromocytoma, which grows slowly, the ON-TOP embedding method is required to provide a special growth environment and improve the culture success rate. This invention provides a reliable research tool for studying the development and metabolic mechanisms of pheochromocytoma.

The invention discloses a catecholamine and metabolite detection kit and application thereof. The kit comprises a calibration product, a quality control product, an internal standard solution, an eluent and a leacheate, efficient enrichment and purification of a target object in a sample can be realized in cooperation with a magnetic microsphere adsorption-elution pretreatment process, and then liquid chromatography-tandem mass spectrometry (LC-MS / MS) detection is performed. Compared with existing solid-phase extraction (SPE), derivatization or protein precipitation and other methods, the scheme is simplified in operation and high in detection efficiency, can more easily meet clinical high-throughput and automatic detection requirements, and can be widely applied to diagnosis and follow-up monitoring of pheochromocytoma, parangganglioma and other diseases.

Provided herein are methods and compositions for reducing the expression and / or activity of an oncogenic transfer RNA (tRNA). Composition for treating cancer in the subject are disclosed, comprising an inhibitor of an oncogenic transfer RNA (tRNA) to a subject in need thereof, wherein the oncogenic tRNA comprises an inhibitory nucleic acid such as ARG-TCT-4-1, an siRNA, an shRNA, an miRNA, an antisense oligonucleotide, or a nucleic acid modification such as a locked nucleic acid, a phosphorothioate modification, a 2′—O-methyl modification, a 2′—O-methoxyethyl modification, a 2′-fluoro modification, a phosphorodiamidate modification, or a mesylphosphoramidate modification. The disclosed compositions are disclosed as treating cancers such as a sarcoma, a glioblastoma, an adrenocortical carcinoma, a cholangiocarcinonma, a melanoma, a glioma, a diffuse glioma, a mature B cell neoplasm, a non-small cell lung cancer, an esophagogastric adenocarcinoma, a pheochromocytoma, a hepatocellular carcinoma, an endometrial carcinoma, a pancreatic adenocarcinoma, a breast carcinoma, an invasive breast carcinoma, a head and neck squamous cell carcinoma, a bladder urothelial carcinoma, a colorectal adenocarcinoma, an ovarian epithelial tumor, a prostate adenocarcinoma, a cervical squamous cell carcinoma, a renal non-clear cell carcinoma, or a renal clear cell carcinoma.

The invention is applicable to the technical field of tumor medicine, and provides application of ANGPT2 as a biomarker in pheochromocytoma and parangganglioma molecular typing and prognosis evaluation. The invention discloses an application of an ANGPT2 gene and an expression product of the ANGPT2 gene as a biomarker in pheochromocytoma and paraganglioma (PPGLs) molecular typing and prognosis evaluation. Through transcriptome sequencing, the specific high expression of ANGPT2 in the C1 subtype of PPGLs is found for the first time, and the expression level of ANGPT2 is significantly related to tumor invasiveness and poor prognosis. Based on the discovery, the invention provides a diagnostic kit containing an ANGPT2 detection reagent, and the kit can be used for molecular typing and prognosis evaluation of PPGLs. Compared with the prior art, the technical scheme provided by the invention has the advantages of simplicity and convenience in detection, low cost, reliable result and the like, and a new tool is provided for accurate diagnosis and treatment of PPGLs.

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).